Bharat Rajagopal Joins Verily as Chief Revenue Officer
Bharat Rajagopal Joins Verily as Chief Revenue Officer
Former Microsoft life sciences commercial leader brings extensive experience advancing digital transformation across healthcare and technology
Verily, an Alphabet precision health technology company, today announced the appointment of Bharat Rajagopal as Chief Revenue Officer. Rajagopal will join Verily’s leadership team and be responsible for the strategy and execution of all commercial revenue generating activities, including driving sales, business development, partnerships, and customer success to advance precision health.
Rajagopal brings more than two decades of experience leading commercial growth and digital transformation at Microsoft. While at Microsoft, Rajagopal held a series of customer-facing leadership roles, most recently, serving as the General Manager of Microsoft’s U.S. Life Sciences and MedTech business. In this role, he led a team of sales, technical, and operational leaders and partnered with pharma, medtech, and life science organizations to advance their digital transformation efforts to bring life-saving therapies to market faster. Rajagopal also partnered with next generation healthcare startups to build and scale on the Microsoft cloud.
“Bharat is a distinguished commercial executive with extensive experience driving technology adoption for some of the most innovative organizations across healthcare,” said Stephen Gillett, Chief Executive Officer at Verily. “His leadership and expertise will be critical as we deepen and scale our customer relationships to deliver on the promise of precision health.”
Prior to his role as General Manager, Rajagopal served as Chief Operating Officer of Microsoft's Gulf Coast Enterprise & Partner Group. In this role, he drove significant enterprise software growth by enabling digital transformation for global customers in high tech, oil, and gas. In addition to his commercial leadership at Microsoft, Rajagopal frequently collaborates with external groups that set industry standards and remove barriers to the adoption of technology across life sciences.
“Over the last 20 years, my work has been focused on partnering with enterprises, including life sciences and medtech companies, to drive the adoption and use of transformative technologies,” said Bharat Rajagopal. “With the recent advances in AI, we have a generational opportunity to discover therapies never imagined before. I’m thrilled to continue my mission at Verily by partnering with organizations across the ecosystem to deliver new data, AI, and technology solutions that accelerate evidence generation and advance precision health.”
About Verily
Verily is an Alphabet health technology company focused on research, care, and health financing to deliver on the promise of precision health and help people live healthier lives. We are uniquely positioned at the intersection of technology, data science, and healthcare to create tools to accelerate evidence generation, products to enable more personalized care, and approaches to make costs more predictable. For more information, please visit: verily.com
Steven Cooper
Head of Media Relations, Verily
sjcoop@verily.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402062031/en/
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing